Italia markets closed

Adocia SA (0QAI.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
8,72+0,36 (+4,31%)
Alla chiusura: 05:53PM GMT

Adocia SA

115 Avenue Lacassagne
Lyon 69003
France
33 4 72 61 06 10
https://www.adocia.com

Settore/i
Settore
Impiegati a tempo pieno97

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Gérard Soula M.B.A., Ph.D.Co-Founder & Chairman of the Board370,62kN/D1945
Mr. Olivier Soula M.B.A., Ph.D.Co-Founder, CEO & Director278,63kN/D1970
Ms. Valérie DanaguezianChief Financial OfficerN/DN/DN/D
Jeremy Benattar Eng., Pharm.D.Marketing & Strategy DirectorN/DN/DN/D
Ms. Geraldine Favre SoulaHuman Resources Development DirectorN/DN/DN/D
Dr. Bertrand AlluisHead of the Analysis Department and Project ManagerN/DN/DN/D
Dr. David DuracherHead of the Pharmaceutical Development & Physical Chemistry Departments and Project ManagerN/DN/DN/D
Dr. Richard CharvetHead of Chemistry Department & Project ManagerN/DN/DN/D
Dr. Grégory MeiffrenHead of the Biology Department & Project ManagerN/DN/DN/D
Rosy Eloy M.D.Chief Medical OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Governance aziendale

L'ISS Governance QualityScore di Adocia SA al 1 marzo 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 10; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.